Mylan Laboratories, Inc. (NASDAQ:MYL)
| CAPS Rating |
|
|---|---|
| Open | $22.78 |
| Previous Close | $22.96 |
| Daily Range | $22.55 - $22.89 |
| 52-Week Range | $15.49 - $25.46 |
| Market Cap | $9.72B |
| P/E Ratio | 20.80 |
| Dividend (Yield) | 0.24 (1.20%) |
| Volume | 2,996,276 |
| Average Daily Volume | 0 |
MYL
VS S&P 500 (SPY)
How do you think MYL will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MYL Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MYL News and Commentary
- UPDATE: US Appeals Court Upholds Dismissal Of Some AstraZeneca Crestor Patent Suits – SmartMoney
- US Appeals Court Upholds Dismissal Of Some AstraZeneca Crestor Patent Lawsuits – SmartMoney
- The Zacks Analyst Blog Highlights: Western Union, Mylan, Valeant Pharmaceuticals, Sanofi and Pfizer – NASDAQ
- Mylan Acquires Two Generics - Analyst Blog – NASDAQ
- CIVETS Watch: US Dollar Is Popular in Egypt, but US Is Not – Minyanville
- Shire and Sangamo Cut a Deal - Analyst Blog – NASDAQ
- Zacks Bull and Bear of the Day Highlights: Mylan, JAKKS Pacific, Chevron, BP plc and ExxonMobil - Pr – NASDAQ
- Mylan, Inc. (MYL) - Bull of the Day – NASDAQ
- 2 Stocks to Beat a Recession – The Motley Fool
- Mylan Inc Enters Oversold Territory - Tale of the Tape – NASDAQ
- Zacks Bull and Bear of the Day Highlights: DaVita, Hhgregg, Mylan, Teva Pharmaceutical and Novartis – NASDAQ
- Medicines Co. Settles with APP - Analyst Blog – NASDAQ
- Mylan Outperforms as Generics Rule - Analyst Blog – NASDAQ
- Is Mylan Hiding Weakness? – The Motley Fool
- Shire, Prasco Ink Deal - Analyst Blog – NASDAQ
- 2012 Newest Biotech Trend – The Motley Fool
- The Zacks Analyst Blog Highlights: Teva Pharmaceuticals, Mylan, Watson Pharma, Dr. Reddy's and Novar – NASDAQ
- More Generic Launches for Mylan - Analyst Blog – NASDAQ
- How Does Pfizer Boost Its Returns? – The Motley Fool
- The Next Trend in Biotech Partnerships – The Motley Fool
RSS Headlines
Fool UK
